2月24日 - ** 药物开发商Summit Therapeutics SMMT.O股价盘前上涨6.2%至23.50美元
** 该公司称，它正在与辉瑞PFE.N合作 (link)，研究其实验性药物ivonescimab与辉瑞的几种癌症靶向疗法（称为抗体药物共轭物(ADCs)）在不同类型肿瘤中的联合应用。
** 根据协议，SMMT将为研究提供 ivonescimab，辉瑞将进行研究
** 研究预计将于今年年中开始
** SMMT的药物此前在中国的一项试验中显示，一些肺癌患者的生存率更高，超过了 (link) Merck的MRK.N大片Keytruda。
** 去年销售额超过 290 亿美元的全球最大药物 Keytruda 在这些研究中表现优异，在过去 12 个月中股价上涨了 5 倍。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.